Takara Bio Grants Transgenomic License for LA-PCR Technology
July 29, 2014     Japanese 
  JCN 
	  Network - Home
JCN Newswire
  Home  |  Companies  | Annual Reports  |  CSR  | News Alerts     
 
Takara Bio Grants Transgenomic License for LA-PCR Technology - JCN Newswire
Share:
Takara Bio Grants Transgenomic License for LA-PCR Technology
 
Takara Bio Grants Transgenomic License for LA-PCR Technology

Tokyo, May 7, 2007 - (JCN Newswire) - Takara Bio Inc. (TSE: 4974) today announced that it has granted Transgenomic, Inc. a worldwide non-exclusive license to make, use and sell LA-PCR related products. Including Transgenomic, the company has nineteen (19) licensees of its LA-PCR technology worldwide. Financial terms of the license were not disclosed.

LA-PCR Technology, invented by Dr. Wayne M. Barnes, is a breakthrough in PCR (Polymerase Chain Reaction) technology that expands its capability and heightens its application potential considerably. LA-PCR technology overcomes the disadvantages and defects of conventional PCR by enabling high-yield amplification of long and complex DNA fragments from genomic DNA. More importantly for the molecular researcher, DNA molecules produced with LA-PCR Technology have significantly fewer mutations than those made using conventional PCR.

The company entered into a Patent Assignment Agreement with Dr. Barnes in April 1996 and acquired all of Dr. Barnes' right, title and interest in and to the patents relating to LA technology. The company continues to promote licensing of this technology as well as sales of its own products worldwide.

About Takara Bio

Takara Bio Inc. (TSE: 4974) is an innovative biotechnology company based in Shiga, Japan. As a world leader in biotechnology research and development, Takara Bio was the first company to market PCR technology in Japan and is also the developer of the RetroNectin(R) reagent, which is a world-standard in gene therapy protocols. In addition to providing research reagents and equipment to the life science research market, Takara Bio has active research and product development activities in the fields of gene and cell-based therapy, and agricultural biotechnology; and is committed preventing disease and improving the quality of life for all people through the use of biotechnology. Through strategic alliances with other industry leaders, the Company aims to extend its reach around the world. More information is available at http://www.takara-bio.com .

Contact:

Corporate Communications
Takara Bio Inc.
E-mail: bio-ir@takara-bio.co.jp
 


May 7, 2007
Source: Takara Bio

Takara Bio (TSE: 4974)

From the Japan Corporate News Network
http://www.japancorp.net
Topic: Press release summary


 
CSR Report Download
Annual Reports

  More >>    
Most Popular


About JCN | Privacy Policy | Terms of Use | JCN Network (日本語)